Technical Analysis for BPMC - Blueprint Medicines Corporation

Grade Last Price % Change Price Change
grade C 71.62 0.00% 0.00
BPMC closed unchanged on Thursday, September 20, 2018, on 71 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Up Down
See historical BPMC trend table...

Date Alert Name Type % Chg
Sep 20 20 DMA Resistance Bearish 0.00%
Sep 18 Crossed Above 50 DMA Bullish 0.93%
Sep 18 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.93%
Sep 18 Pocket Pivot Bullish Swing Setup 0.93%
Sep 18 Multiple of Ten Bullish Other 0.93%
Sep 18 Lower Bollinger Band Touch Weakness 0.93%
Sep 17 Fell Below 20 DMA Bearish 4.30%
Sep 17 Fell Below 50 DMA Bearish 4.30%
Sep 17 New Downtrend Bearish 4.30%
Sep 17 Expansion Pivot Sell Setup Bearish Swing Setup 4.30%

Older signals for BPMC ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Blueprint Medicines Corporation, a biopharmaceutical company, focuses on the development of the highly selective kinase inhibitors for genomically defined cancer subsets. The company's lead drug candidates include BLU-285, which targets KIT Exon 17 and PDGFRa D842V, abnormally active receptor tyrosine kinase mutants for patients with systemic mastocytosis, a myeloproliferative disorder of the mast cells, and defined subsets of patients with gastrointestinal stromal tumor, as well as targets the KIT D816V mutation; and BLU-554, an orally available, potent, selective, and irreversible inhibitor, which targets FGFR4. It is also developing a drug candidate to target RET, a receptor tyrosine kinase that can becomes abnormally activated when a portion of the gene that encodes RET is joined to part of another gene; and RET resistant mutants that would arise from treatment with first generation therapies, as well as a program that targets rare genetic diseases. The company has a research, development, and commercialization agreement with Alexion Pharma Holding to research, develop, and commercialize drug candidates for an undisclosed activated kinase target, which is the cause of a rare genetic disease. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was founded in 2008 and is based in Cambridge, Massachusetts.
Is BPMC a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 109.0
52 Week Low 57.44
Average Volume 314,947
200-Day Moving Average 78.2074
50-Day Moving Average 69.2968
20-Day Moving Average 73.348
10-Day Moving Average 73.339
Average True Range 2.8152
ADX 25.24
+DI 21.199
-DI 22.0213
Chandelier Exit (Long, 3 ATRs ) 70.3444
Chandelier Exit (Short, 3 ATRs ) 75.9536
Upper Bollinger Band 78.0049
Lower Bollinger Band 68.6911
Percent B (%b) 0.31
BandWidth 12.698097
MACD Line 0.5037
MACD Signal Line 1.1747
MACD Histogram -0.671
Fundamentals Value
Market Cap 2.8 Billion
Num Shares 39.1 Million
EPS -3.12
Price-to-Earnings (P/E) Ratio -22.96
Price-to-Sales 103.31
Price-to-Book 7.06
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 75.61
Resistance 3 (R3) 75.87 74.81 74.95
Resistance 2 (R2) 74.81 73.79 74.68 74.72
Resistance 1 (R1) 73.21 73.16 72.68 72.95 74.50
Pivot Point 72.15 72.15 71.88 72.02 72.15
Support 1 (S1) 70.55 71.13 70.02 70.29 68.74
Support 2 (S2) 69.49 70.50 69.36 68.52
Support 3 (S3) 67.89 69.49 68.30
Support 4 (S4) 67.63